Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Basal Cell 2Basal Cell Nevus Syndrome 2Solid Tumor 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Keratosis, Actinic 1

Interventions

Cyclophosphamide 41Peripheral Blood Stem Cell Transplantation 40fludarabine phosphate 36Whole-Body Irradiation 27Mycophenolic Acid 27Tacrolimus 23Busulfan 23Cyclosporine 22Antilymphocyte Serum 20Etoposide 17Methotrexate 16Filgrastim 16Melphalan 14romidepsin 13Radiotherapy 13Flow Cytometry 12Methylprednisolone 10Brentuximab Vedotin 10Therapeutics 9Psychiatric Rehabilitation 9Lenalidomide 8pembrolizumab 7fludarabine 7Sirolimus 7Rituximab 7Bortezomib 7Bexarotene 7mogamulizumab 6Polymerase Chain Reaction 6Gemcitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell, Cutaneous × tazarotene × Clear all
NCT00779896 2008-10-24

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

McGill University

Phase 1/2 Unknown
15 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡